Support for sharing personal health data to advance artificial intelligence in healthcare exists within the UK public, but is heavily conditional, according to findings from a series of focus groups commissioned by Medical Xpress. The research indicates a willingness to contribute data is contingent on robust safeguards regarding privacy, security, and the ethical application of AI technologies.
Participants expressed concerns about potential misuse of their data, particularly regarding commercial interests and the possibility of discrimination. A key theme emerging from the discussions was the need for transparency regarding how AI algorithms are developed and deployed, and who benefits from their use. Individuals wanted assurances that their data would be used to improve healthcare outcomes for all, rather than to generate profit for private companies.
The findings arrive at a time of increasing integration of AI within the National Health Service (NHS). The NHS Confederation recently highlighted ongoing developments in the health and care sector, signaling a broader push towards technological innovation. However, this progress is occurring alongside scrutiny of specific AI partnerships.
A recent deal between the NHS and the US-based AI firm Palantir has faced questions following the revelation of internal concerns among officials, as reported by The Guardian. The concerns center on the scope of Palantir’s access to patient data and the potential for the company to exert undue influence over healthcare decision-making. The contract, intended to improve data management and streamline NHS operations, has sparked debate about the balance between technological advancement and patient privacy.
According to The Engineer, patients themselves are increasingly driving the demand for AI-powered healthcare solutions. Individuals are seeking more personalized and proactive care, and are open to utilizing AI tools to achieve these goals. However, this patient-led demand is coupled with a strong expectation of data protection and ethical oversight. The focus groups revealed a desire for greater patient control over their health data, including the ability to access, modify, and withdraw their information.
The Medical Xpress report did not detail specific mechanisms for addressing these concerns, but the focus group participants consistently emphasized the importance of clear regulations and independent oversight. Participants also suggested the need for public education campaigns to raise awareness about the benefits and risks of AI in healthcare, and to empower individuals to make informed decisions about their data.
The NHS has not yet responded to a request for comment regarding the focus group findings or the implications for its ongoing AI strategy. A scheduled review of the Palantir contract is expected to take place in the spring of 2026, and will likely address some of the concerns raised by officials and the public.
